Genesis Therapeutics is pioneering artificial intelligence guided rational drug design to address severe unmet medical needs for patients. Our San Diego lab seeks a motivated and enthusiastic structural biologist to enhance our expertise in X-ray crystallography, cryo-electron microscopy, and structure based drug design. The successful candidate will collaborate and/or lead multidisciplinary drug discovery projects, manage CRO resources and develop structural biology strategy.
\n Job Responsibilities/What you will do:Develop and implement structural biology strategies for drug discovery programs from target evaluation to candidate nominationLead and coordinate structural biology research projects, including managing CRO activitiesGuide protein-small molecule complex structures to support structure-based drug design and platform evolutionCollaborate with other drug discovery disciplines (biology, medicinal chemistry, DPMK, software engineers, computational chemists) to drive hypothesis driven decisions and enhance the platformRegularly communicate and engage with project team members and management Education and Experience Requirements/What you'll bring:PhD in crystallography, cry-EM, biophysics, or relevant structural biology degree with 8+ years of industrial drug discovery experience orMS in structural biology with at least 14 years of industrial drug discovery experienceExpertise in protein production, purification, X-ray crystallography and cryo-EMExperience across oncology and immunology targetsEffective management of external CRO structural biology resourcesStrong understanding of molecular modeling and computational biologyProficiency in characterizing protein-ligand interactions using biophysical methods
\nGenesis Therapeutics is unifying AI and biotech to discover novel and breakthrough treatments for patients with severe and devastating conditions. Genesis was founded on groundbreaking molecular ML research and since has established itself as the industry leader in AI for small molecule drug discovery. Our team of accomplished biotech leaders and expert drug hunters joins forces with deep learning researchers and software engineers who are pioneering predictive and generative AI technologies for molecules. Our team has created the industry's most advanced molecular AI platform called GEMS (Genesis Exploration of Molecular Space), to accelerate and optimize small molecule drug discovery and to enable the discovery of novel first-in-class and best-in-class small molecule drugs for challenging and/or undruggable targets. The company has leveraged GEMS to build an internal pipeline with multiple programs against high-value targets, including data-poor and canonically undruggable targets where GEMS is uniquely advantaged. In addition, Genesis has three AI platform collaborations across a range of therapeutic areas, with Gilead Sciences, Eli Lilly, and Genentech. We raised a $200M series B in August 2023, and have raised over $300M in funding from top technology and biotech investors, including Andreessen Horowitz, Rock Springs Capital, T. Rowe Price, Fidelity, Radical Ventures, NVentures (NVIDIA's VC arm), BlackRock, and Menlo Ventures. Genesis is headquartered in Burlingame, CA, with a fully integrated laboratory in San Diego. We are proud to be an inclusive workplace and an Equal Opportunity Employer.